They Built a $1 Billion Vibe-Coding Empire. Now Their Biggest Partners Are Coming for It

Amjad Masad and Haya Odeh built Replit together from scratch. Can they defend its position as an industry juggernaut?
Yahoo Finance

REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review

The last time I spoke about Replimune Group, Inc. (REPL), it was with a Seeking Alpha article entitled "Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating." With respect to this ...
Yahoo Finance

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Morningstar%2c Inc.

Rudrabhishek Enterprises Ltd Ordinary Shares REPL

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

AI coding agents are blowing through budgets — Replit, Kilo Code, and Symbotic explain how they're managing it

Replit, Kilo Code, and Symbotic engineering leaders reveal how they track AI coding costs and stop runaway token spend before it wrecks the budget.
Ars Technica

OpenAI says its AI agent broke out of testing sandbox to hack Hugging Face

OpenAI says an agent powered by its LLM models escaped its sandboxed testing environment to infiltrate Hugging Face’s servers as part of an overzealous attempt to obtain solutions to a benchmark test.
Seeking Alpha

Replimune's RP1 Drug Probably Works, But It's Not A Buy Yet

Replimune Group faces a pivotal FDA decision for RP1 in advanced melanoma, with a Sell rating reflecting approval odds and the current price. RP1 demonstrates real antitumor activity and durable ...
CNN

An OpenAI test model escaped and broke into a real company’s servers

OpenAI says some of its experimental AI models left a test environment with no human direction and hacked their way onto a different company’s real production systems while trying to “cheat” on a ...
SBS

AusAlert emergency warning test: What to do if you didn't receive the alert

With millions of Australians receiving a loud siren and text message simultaneously across the country for the national AusAlert test, many had prepared their phones ahead of the warning. AusAlert is ...
Hosted on MSN

REPL stock tracks best day ever: This analyst sees higher approval odds for Replimune’s melanoma after ‘overwhelmingly positive’ panel outcome

Cantor Fitzgerald upgraded Replimune to Overweight from Neutral without a price target The Adcom panel voted 10-3 in favor of RP1 ahead of the FDA’s official decision on Aug 2. The panel said the ...